European Medicines Agency's Fergus Sweeney: Increasing Inspection Coverage in the Wake of Globalisation
Add bookmarkWherever you sit in the world as a regulator, most of the clinical trials you receive in marketing applictaions, most of the manufacturing that takes place for products is taking place in terrioties outside of the juristicion of your regulatory system. In this interview Fergus Sweeney, Head of Compliance & Inspection Patient Health Protection, European Medicines Agency (EMA), speaks to Andrea Charles from Pharma IQ, about increading inspection coverage, harmonisation and exchange.
Interview filmed at DIA 2011 47th Annual Meeting.
[eventpdf]
 |
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
 |
What are the 7 Deadly Sins of Quality Assurance and Quality Control?
Download our free QA QC eBook now to find out!
Wherever you sit in the world as a regulator, most of the clinical trials you receive in marketing applictaions, most of the manufacturing that takes place for products is taking place in terrioties outside of the juristicion of your regulatory system. In this interview Fergus Sweeney, Head of Compliance & Inspection Patient Health Protection, European Medicines Agency (EMA), speaks to Andrea Charles from Pharma IQ, about increading inspection coverage, harmonisation and exchange.
